BioMarin Pharmaceutical (BSP:B1MR34) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1MR34 BioMarin Pharmaceutical Inc BSP:B1MR34
67 GF Score
Price R$170.37
GF Value R$204.24
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical FFO per Share?

FFO per Share only applies to REITs.

BSP:B1MR34
67GF Score
BioMarin Pharmaceutical Inc BSP:B1MR34
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMarin Pharmaceutical (BSP:B1MR34) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of R$170.37 is trading 16.6% below its estimated GF Value™ of R$204.24. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BSP:B1MR34:

  • FFO per Share:
  • GF Value™: R$204.24 vs. price of R$170.37 (16.6% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BSP:B1MR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
67GF Score

Get the complete analysis for BSP:B1MR34

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$170.37
Price
R$204.24
GF Value